On May 6, 2020 NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported that it has issued a second tranche of Convertible Bonds under the financing agreement published on April 23, 2020 (Press release, NOXXON, MAY 6, 2020, View Source [SID1234557161]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The investor, Atlas Special Opportunities, LLC, has received 483 Notes (including 8 Convertible Bonds issued in relation to the transaction fee) with a nominal value of €1,000 each.

NOXXON maintains an updated summary table of issued convertible bonds in the Investors’ section of its website.

The characteristics, terms, conditions and dilutive potential of the financing may be found in the Annex to the press release published on April 23, 2020 available on the company’s website.